ArticleFrontiers in endocrinology2025
Plasma-derived exosomal miRNAs as potentially novel biomarkers for type 2 diabetes mellitus with abdominal obesity.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular Vesicles in Obesity: From Pathophysiological Mediators to Therapeutic Tools.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To explore the plasma exosomal miRNA expression profiles in patients with abdominal obesity and type 2 diabetes mellitus (T2DM), identify differentially expressed exosomal m4RNAs, and evaluate the potential of selected exosomal miRNAs as biomarkers for abdominal obesity-related T2DM. Methods: In the screening phase, high-throughput sequencing was used to detect the plasma exosomal miRNA expression profiles of non-abdominal obese individuals with normal glucose metabolism (NAO/NG, N = 4), abdominal obese individuals with normal glucose metabolism (AO/NG, N = 4), and abdominal obese T2DM patients (AO/T2DM, N = 4). Five differentially expressed miRNAs were identified. In the independent validation phase, RT-qPCR was performed to validate the expression of these miRNAs in the NAO/NG group (N = 18), AO/NG group (N = 14), and AO/T2DM patients (N = 17). The correlation between the miRNA levels in AO/T2DM patients and clinical features was evaluated, and the diagnostic value of the selected miRNAs for AO/T2DM was analyzed using receiver operating characteristic (ROC) curves. Results: In the screening phase, 5 exosomal miRNAs showed sequential changes among the NAO/NG, AO/NG, and AO/T2DM groups. The AO/NG group specifically expressed 16 exosomal miRNAs, while the AO/T2DM group specifically expressed 7 exosomal miRNAs. In the independent validation phase, the expression of exosomal miRNAs hsa-let-7g-5p and PC-3p-13356 in plasma increased progressively across the NAO/NG, AO/NG, and AO/T2DM groups. The expression of exosomal hsa-miR-6505-5p in the AO/T2DM group was significantly higher than that in the AO/NG and NAO/NG groups. The expression of hsa-miR-1229-3p in plasma exosomes was significantly lower in the AO/NG group compared to the NAO/NG group, but higher in the AO/T2DM group compared to the AO/NG group. No differences were detected in the expression of hsa-miR-4750-5p among the groups. The areas under the ROC curves (AUC) for plasma exosomal hsa-let-7g-5p, PC-3p-13356, and hsa-miR-6505-5p were 0.857, 0.786, and 0.878, respectively. When combined, these three miRNAs showed high diagnostic value for abdominal obesity T2DM (AUC = 0.891). Conclusions: Patients with abdominal obesity and T2DM have a unique exosomal miRNA expression profiles. These characteristic exosomal miRNAs could serve as novel biomarkers for identifying such patients and may help in further understanding the pathogenesis of abdominal obesity-related T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.